Assessment of ¹⁸F-FET PET-based response in patients with gliomas using the PET RANO 1.0 criteria.

ABSTRACT:

Background

We evaluated the amino acid PET-based response assessment criteria (PET RANO 1.0) for their proficiency in predicting longer survival in patients with gliomas undergoing adjuvant temozolomide chemotherapy.

Methods

In a previous study, 38 patients with newly diagnosed grade 4 gliomas according to the World Health Organisation classification underwent O-(2-[¹⁸F]fluoroethyl)-l-tyrosine (¹⁸F-FET) PET at baseline and after the second cycle of adjuvant temozolomide chemotherapy. The ability of PET parameter changes to predict favorable progression-free and overall survival (PFS, OS) of ≥9 and ≥15 months was evaluated. Here, we performed a post hoc analysis of these PET data to evaluate the PET RANO 1.0 criteria. In addition, the value of the

SUBMITTER: Ceccon G 

PROVIDER: S-EPMC12746607 | biostudies-literature | 2025 Jan-Dec

REPOSITORIES: biostudies-literature